Skip to content
Screener

Innoviva, Inc. INVA Operating Cash Flow

Operating Cash Flow at other companies

Pfizer logo
PfizerPFE
$2.62B+12.0%
Merck & Co. logo
Merck & Co.MRK
$5.37B+63.1%
AbbVie logo
AbbVieABBV
$3.83B+134%
Insmed logo
InsmedINSM
-$88.83M+56.8%
Savara logo
SavaraSVRA
-$33.05M-21.5%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$41.89M+38.4%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.53B+33.1%
Enterprise value$1.22B+2.1%
P/E4.3×-25.4×
P/S3.5×+0.4×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Accrued interest payable(4)
Income tax payable2,6451,921
Deferred revenue1,7451,999
Net cash provided by operating activities87,25492,690
Cash flows from investing activities
Purchases of trading securities(34,999)(34,674)
Purchases of equity and other long-term investments(30,021)
Proceeds from trading securities5,097

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s operating cash flow?
Innoviva, Inc. (INVA) reported operating cash flow of $51.97M in Q2 2026.
How has Innoviva, Inc.'s operating cash flow changed year-over-year?
Innoviva, Inc.'s operating cash flow increased by 17.9% year-over-year, from $44.07M to $51.97M.
What is the long-term trend for Innoviva, Inc.'s operating cash flow?
Over 4 years (2021 to 2025), Innoviva, Inc.'s operating cash flow has grown at a -14.2% compound annual growth rate (CAGR), from $363.81M to $196.93M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Innoviva, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude